New immunosuppressive drugs in dermatology (mycophenolate mofetil, tacrolimus): unapproved uses, dosages, or indications.
Assmann
Till
T
Department of Dermatology, University of Dusseldorf, Dusseldorf, Germany. assmannt@uni-duesseldorf.de
Ruzicka
Thomas
T
D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects; D003880:Dermatology / Q000592:standards / Q000639:trends; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D017277:Drug Approval; D004363:Drug Utilization; D005260:Female; D005858:Germany; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D009173:Mycophenolic Acid / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives; D011379:Prognosis; D018570:Risk Assessment; D012871:Skin Diseases / Q000188:drug therapy* / Q000276:immunology; D016559:Tacrolimus / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
D003879:Dermatologic Agents; D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid; D016559:Tacrolimus